drugset / Trial / NCT05048082
A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
NaSingle-groupOpen-labelDiagnostic
Summary
This Phase 2 study is an open-label, single-arm trial where each patient is his/her own "intrapatient" control. All patients will receive a single dose of pegsitacianine prior to standard of care surgery.
Timeline
- Start
- 2022-04-13
- Primary completion
- 2022-08-31
- Completion
- 2022-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pegsitacianine | Diagnostic / imaging agent | 1 mg/ml | — |